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Abstract
Background: Retroviral vectors are widely used tools for gene delivery and gene therapy. They are useful for gene
expression studies and genetic manipulation in vitro and in vivo. Many retroviral vectors are derived from the
mouse gammaretrovirus, murine leukemia virus (MLV). These vectors have been widely used in gene therapy
clinical trials. XMRV, initially found in prostate cancer tissue, was the first human gammaretrovirus described.
Findings: We developed a new retroviral vector based on XMRV called pXC. It was developed for gene transfer to
human cells and is produced by transient cotransfection of LNCaP cells with pXC and XMRV-packaging plasmids.
Conclusions: We demonstrated that pXC mediates expression of inserted transgenes in cell lines. This new vector
will be a useful tool for gene transfer in human and non-human cell lines, including gene therapy studies.
Keywords: XMRV, retroviral vector, transduction
Findings
Retroviral vectors offer a highly efficient method of
stable gene transfer in mammalian cells due to their
ability to integrate into the host genome [1,2]. More-
over, the common genetic architecture of most retro-
viruses allows the development of similar retroviral
vectors with different potentials for cell entry via virus-
specific receptors and different capabilities for gene
expression mediated by diverse retroviral promoters [3].
Current retroviral vectors used for gene transfer are
replication defective. Trans-expression of retroviral
structural proteins from non vector-homologous plas-
mids avoids the production of replication competent
retrovirus (RCR) [4,5]. Many retroviral vectors are
derived from murine leukemia virus (MLV) in both,
ecotropic and amphotropic versions [6,7]. Lentiviral vec-
tors based on HIV may offer advantages because of
their lower insertion frequency in crucial loci involved
in cell growth regulation and their ability to transduce
non-dividing cells [8,9]. Nevertheless, MLV-derived ret-
roviral vectors have been used extensively, including in
more than 300 gene therapy clinical trials [10]. In addi-
tion, retroviral vectors derived from avian sarcoma
leukosis virus (ASLV; [11]), spleen focus-forming virus
(SFFV; [12]), and Mason-Pfizer monkey virus (MPMV;
[13]), have been developed among others.
In 2006, the xenotropic murine-leukemia-virus related
gammaretrovirus (XMRV) was discovered in a subset of
human prostate cancer (PCa) tissue samples [14]. Subse-
quently, additional studies demonstrated that XMRV
uses the XPR1 receptor to initiate infection, and that
the virus is sensitive to IFN-b and RNase-L, a final
effector of the IFN-b mediated antiviral response [15].
Since XMRV shows the basic structure of gammaretro-
viruses, we developed a panel of packaging plasmids and
retroviral vectors derived from XMRV. Here we demon-
strate their potential use as gene transfer vectors for in
vitro assays.
Initially, we constructed a plasmid to evaluate the pro-
moter activity of the U3 region of the XMRV LTR
derived from 22Rv1 cells. A fragment of 554 base pairs
was isolated by PCR with oligonucleotide primers
XMRV-U3-f and XMRV-U3-r (Table 1), and inserted
into the plasmid vector, pCR2.1-Topo (Invitrogen).
Digestion with the enzymes Sac-I and Xho-I released a
fragment of 632 base pairs, which was inserted into the
plasmid vector, pGL3-Basic (Promega). The pGL3-
XMRV-U3-luc expression plasmid was used to transfect
Hep G2, HEK-293, SiHa, 22Rv1, and PC-3 cell lines.
Luciferase expression was assayed 72 hours later. Similar
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levels of transcription were observed in all five cell lines
tested and little or no cell type specificity of the XMRV
promoter was found. Moreover, the level of luciferase
expression mediated by the XMRV promoter was simi-
lar to that mediated by the SV40 virus early region pro-
moter in each cell line (Figure 1).
An XMRV-derived retroviral gene transfer vector,
pXC, was constructed in the pBluescript II KS plasmid.
Genomic DNA from 22Rv1 cells was used as template
for XMRV sequence isolation by PCR amplification. The
CMV immediate early enhancer (CMV-IEE) was posi-
tioned 5’ to the XMRV LTR and XMRV RNA-packaging
signal, followed by the CMV immediate early promoter
(CMV-IEP) driving a reporter gene (GFP or luciferase),
the XMRV polypurine tract, and a 3’ XMRV LTR (Fig-
ure 2). GFP or luciferase genes were inserted in the
Xho-I/Sal-I and Xba-I sites. XMRV vector packaging
plasmids pcDNA3.1/Hygro-XMRVgagpol and
pcDNA3.1/Zeo-XMRVenv were also created by amplifi-
cation of the gag-pol and env genes, respectively. The
templates for isolation of XMRV structural genes were
Table 1 Oligonucleotide primers used in this study.
Oligonucleotide 5’ modification Sequence
Luciferase expression plasmid
XMRV-U3-f - GCCCTGGTTCTGACCCAACAGTAT
XMRV-U3-r - AAAGGCTTTATTGGGAACACGGGT
Vector plasmid
CMV-IEE-f SacI GAGCTCCGCGTTACATAACTTACGG
CMV-IEE-r MfeI CAATTGCAAAACAAACTCCCATTGACG
XMRV-LTR5-f MfeI CAATTGTGAAAGACCCCACCATAAGG
XMRV-Δgag-r AvrII CCTAGGACGATCCCGAGAACCGTAAC
CMV-IEP-f AvrII CCTAGGGTTGACATTGATTATTGAC
CMV-IEP-r XhoI CTCGAGGTCTGCTTATATAGACC
XMRV-PPT-LTR3-f XbaI TCTAGAATTTCGGTAGTGCAGGCCCTGG
XMRV-PPT-LTR3-r SpeI ACTAGTAATGAAAGACCCCCGAGCTGGG
Packaging plasmid gag-pol
XMRV-gagpol-f NheI GCTAGCATCATGGGACAGACCGTAACTAC
XMRV-gagpol-r NotI GCGGCCGCTTAGGGAAAGTGTCTGTCATCGT
Packaging plasmid env
XMRV-env-f KpnI GGTACCCATGGAAATGCCAGCGTTCTCAA
XMRV-env-r NotI GCGGCCGCGCTAGCGTGCTAAGCCTTAT
Figure 1 Promoter activity of XMRV U3 region. The pGL-XMRV-
U3-Luc plasmid was used to transfect five cell lines and luciferase
activity was compared to the activity of cells transfected with pGL3
SV40-Luc. Data are represented as the mean of triplicates ±
standard error (s.e.).
Figure 2 Vectors and packaging plasmids. Schematic maps of (A)
XMRV-derived vectors, and (B) XMRV vector packaging plasmids.
Cervantes-Garcia et al. Virology Journal 2011, 8:284
http://www.virologyj.com/content/8/1/284
Page 2 of 4
the VP62 clone [14] for the gag-pol gene, and genomic
DNA from the 22Rv1 line for the env gene. Primers
used for these steps are described in Table 1.
XMRV structural proteins were expressed in LNCaP
cells, since these cells satisfactorily support XMRV pro-
tein expression and replication [16,17]. LNCaP cells
were transfected with the packaging plasmids (50 μg
each) using Lipofectamine and XMRV Gag and Env pro-
tein expression was detected by SDS-PAGE followed by
western blotting (Figure 3). Ninety-six hours post-trans-
fection, cells were harvested and proteins were extracted
with lysis buffer (1% Triton X-100, 10 mM Tris-HCl pH
7.5, 50 mM KCl, 2 mM MgCl2, 0.5 mM PMSF, 0.02
mM b-mercaptoethanol, and protease inhibitor cocktail).
The XMRV capsid protein (p30) and surface glycopro-
tein (gp70) were detected using rat monoclonal anti-p30
antibody (kindly provided by Drs. Sandra and Francis
Ruscetti), goat anti-gp70 serum (kindly provided by Dr.
John Elder), goat anti-rat IgG conjugated to horseradish
peroxidase (HRP; Invitrogen), and chicken anti-goat IgG
conjugated to HRP (Santa Cruz Biotech) respectively.
HRP activity was detected by chemiluminescence using
a commercial kit (Pierce).
Lipofectamine mediated triple transfection of LNCaP
cells with the XMRV-derived vector pXC-Luc or pXC-
GFP and two XMRV vector packaging plasmids,
pcDNA3.1/Hygro-XMRVgagpol and pcDNA3.1/Zeo-
XMRVenv, were used to produce XMRV-derived retro-
viral vectors in the culture media. Cell free supernatants
were filtered 72 hours after transfection to produce
XMRV vector stocks. Vector stocks were centrifuged
onto LNCaP cells at 2500 RPM for 90 minutes at room
temperature (spinfected) in the presence of 8 μg/mL
polybrene. Seventy-two hours later, luciferase expression
in the spinfected LNCaP cells was assayed with a com-
mercial assay kit (Dual-Glo Luciferase Assay System,
Promega). The level of luciferase expression achieved in
LNCaP cells transduced with pXC-Luc was more than
320-fold greater than the background expression follow-
ing transduction with pXC-GFP (Figure 4). Luciferase
expression mediated by pXC-Luc, however, was lower
than expression in LNCaP cells transfected with pGL3
CMV-Luc.
293T and HeLa cells were also transduced with pXC-
Luc and these cells were analyzed for luciferase expres-
sion 72 hours later along with LNCaP cells (Figure 5).
Consistent with previous reports, HeLa and 293T cells
were transduced with pXC, but luciferase expression
was lower than in LNCaP cells.
Conclusions
Many retroviral vectors for gene transfer are derived
from murine gamma-retroviruses. Nevertheless, to our
knowledge, the pXC vector and its associated cell packa-
ging system described here constitute the first retroviral
vector system for gene transfer based on a likely human
gammaretrovirus, with particular tropism for human
cells and tissues. Our results suggest that the pXC vec-
tor is a useful tool for gene transfer in human cells and
it is possible that this vector will contribute to elucida-
tion of the interactions of XMRV and its human host.
In addition, this new XMRV-derived retroviral vector
has the potential to be used for stable transfection of
human cells and for preclinical studies of gene therapy.
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Figure 3 XMRV structural proteins. Western blots were performed
for detection of the p30 capsid subunit of Gag and the gp70
surface glycoprotein subunit of Env in LNCaP cells.
Figure 4 Gene expression mediated by XMRV-derived vector in
LNCaP cells. Gene transfer vector XC-Luc or XC-GFP were used to
transduce LNCaP cells. Luciferase activity was measured 72 hours
after transduction. As a positive control, LNCaP cells were
transfected with the plasmid pGL3 CMV-Luc using Lipofectamine.
Data are represented as the mean of triplicates ± standard error (s.
e.).
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Figure 5 Transduction of different cell lines with the XMRV-
derived vector. Luciferase activity in LNCaP, HeLa, and 293T cell
lines 72 hours after transduction with the XMRV-derived vector,
pXC-luc. Data are represented as mean of triplicates ± standard
error (s.e.).
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